Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
Sponsor: Adicet Therapeutics
Summary
The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years from the first administration of Adicet Bio allogeneic γδ CAR T cell product, subjects will be assessed for long-term safety and survival through collection of data that include safety, efficacy, pharmacokinetics and immunogenicity.
Official title: Long-term Follow-up Protocol for Subjects Treated With Adicet Allogeneic Gamma Delta (γδ) CAR T Cell Investigational Products
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2022-02-14
Completion Date
2039-08
Last Updated
2026-04-09
Healthy Volunteers
No
Conditions
Interventions
ADI-001
No study drug is administered in this study. Patients who have received Adicet allogeneic γδ CAR T cell therapy will be evaluated in this trial for long-term safety and efficacy
Locations (5)
Blood and Marrow Transplant Program
Palo Alto, California, United States
Norton Cancer Institute
Louisville, Kentucky, United States
Baylor Scott & White Research Institute
Dallas, Texas, United States
MD Anderson Caner Center
Houston, Texas, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States